Provectus Pharmaceuticals, Inc. (PVCT.OB)
Oncology Corporate Profile
- Products & Overview
- Recent News
HQ Location
7327 Oak Ridge Highway, Suite AKnoxville, TN 37931
Company Description
Provectus Pharmaceuticals is a development-stage biopharmaceutical company that develops therapies that focus on oncology and dermatology. These therapies are designed to treat metastatic melanoma, breast cancer, and liver cancer. Provectus is currently conducting Phase II clinical trials on PV-10. PV-10 is Provectus’ propriety product designed to treat metastatic melanoma. Provectus also develops many over-the-counter products consisting of antiperspirants and sterilizers. Provectus was founded in 2002.
Website: http://www.provectuscorp.com
Commercial Products
This company does not have any commercial productsPipeline Products
- Brand
- Generic
- Investigational
| Brand / Product | Class | Area of Study | Phase | Partnership |
|---|---|---|---|---|
| PV-10 | rose bengal disodium | Metastatic Melanoma | II |
View additional information on product candidates here »
Recent News Headlines
[Business Wire] - KNOXVILLE, Tenn.----Provectus Pharmaceuticals, Inc. , a development-stage oncology and dermatology biopharmaceutical company, will present at the Rodman & Renshaw 12th Annual Healthcare Conference in New York City on September 14, 2010 at 3:15 p.m.
[Business Wire] - KNOXVILLE, Tenn.----Provectus Pharmaceuticals, Inc. , a development-stage oncology and dermatology biopharmaceutical company, has signed an agreement with Numoda Capital Innovations LLC to license its TruPoints® strategic partnering platform.
[Business Wire] - KNOXVILLE, Tenn.----Provectus Pharmaceuticals, Inc. reports on its first half 2010 clinical and corporate accomplishments, as well as its clinical development plans, in a letter to shareholders from Craig Dees, Ph.D., CEO of Provectus.
[PR Newswire] - Provectus Pharmaceuticals, Inc. , a development-stage oncology and dermatology biopharmaceutical company, has announced additional positive data from its Phase 2 clinical trial of PV-10 for metastatic melanoma. Â The data, on changes in visceral and nodal metastases following chemoablation of cutaneous melanoma lesions with PV-10, was presented by Dr.
(Provectus) June 7, 2010 - Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has announced additional positive data from its Phase 2 clinical trial of PV-10 for metastatic melanoma.
(MarketWatch) May 21, 2010 - Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has announced further positive data on the first forty subjects in its Phase 2 clinical trial of PV-10 for metastatic melanoma, with an objective response ("OR") observed in 61% of subjects and a mean Progression Free Survival ("PFS") of at least 11.1 months among those subjects achieving an OR.
KNOXVILLE, Tenn.----Provectus Pharmaceuticals, Inc. , a development-stage oncology and dermatology biopharmaceutical company, has announced further positive data on the first forty subjects in its Phase 2 clinical trial of PV-10 for metastatic melanoma, with an objective response observed in 61% of subjects and a mean Progression Free Survival of at least 11.1 months among those subjects achieving an OR.
KNOXVILLE, Tenn.----Provectus Pharmaceuticals, Inc. , a development-stage oncology and dermatology biopharmaceutical company, announced today that it has held an end-of-Phase 2 meeting with the U.S.
(Forbes) April 29, 2010 - Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that it has held an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) to seek consensus on clinical program scope and endpoints for licensure of PV-10 for metastatic melanoma.
KNOXVILLE, Tenn.----Provectus Pharmaceuticals, Inc. , a development-stage oncology and dermatology biopharmaceutical company, announces that Craig Dees, Ph.D., CEO, will appear at the CFA Society of Nevada.
KNOXVILLE, Tenn.----Provectus Pharmaceuticals, Inc. , a development-stage oncology and dermatology biopharmaceutical company, announced today that data from its Phase 2 study of PV-10 for metastatic melanoma has been accepted for presentation at the 2010 American Society of Clinical Oncology Scientific Program to be held on June 4 – 8, 2010 in Chicago, Illinois.
KNOXVILLE, Tenn.----Provectus Pharmaceuticals, Inc. , a development-stage oncology and dermatology biopharmaceutical company, announced today that Dr. Sanjiv Agarwala, in his presentation at the Seventh International Symposium on Melanoma and Other Cutaneous Malignancies on March 12, 2010, commented on the involvement of the immune system in response to PV-10 therapy and its role in the “bystander effect” in treating metastatic melanoma.
KNOXVILLE, Tenn.----Provectus Pharmaceuticals, Inc. , a development-stage oncology and dermatology biopharmaceutical company, announced today that it has received gross proceeds of approximately $7.5 million in a private placement offering to institutional and accredited investors.
KNOXVILLE, Tenn.----Provectus Pharmaceuticals, Inc. , a development-stage oncology and dermatology biopharmaceutical company, announced today that it has signed agreements with various institutional and accredited investors for the private placement of an aggregate of approximately 7.1 million shares of its convertible preferred stock and warrants to purchase approximately 3.55 million shares of its common stock at an exercise price of $1.00 per share pursuant to a Securities Purchase Agreement.
KNOXVILLE, Tenn.----Please replace the release with the following corrected version due to multiple revisions.
KNOXVILLE, Tenn.----Please replace the release with the following corrected version due to multiple revisions.
KNOXVILLE, Tenn.----Provectus Pharmaceuticals, Inc. , a development-stage oncology and dermatology biopharmaceutical company, announced today that Dr. Sanjiv Argawala, Principal Investigator for Provectus’ Phase 2 PV-10 trial site at St.